Skip to main navigation Skip to search Skip to main content

Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction

  • Huei Chun Liu
  • , Hsin Hsien Chen
  • , Chia Shin Ho
  • , Jui Feng Chang
  • , Chia Chun Lin
  • , Ming Jang Chiu
  • , Ta Fu Chen
  • , Chaur Jong Hu
  • , Sui Hing Yan
  • , Yu Sun
  • , Shieh Yueh Yang*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Concentrations of plasma biomarkers associated with Alzheimer’s disease have been reported to be as low as several tens of picograms/milliliter (pg/ml). However, in assays measuring these biomarkers, it is likely that repeated measurements are necessary to obtain reliable values. Methods: We performed assays as a single test or as duplicate, quadruplicate, fivefold and tenfold repeated tests, on samples spiked with different concentrations of amyloid β 1–40 (Aβ1–40; 1–1000 pg/ml), Aβ1–42 (1–30,000 pg/ml) and total Tau protein (T-Tau; 0.1–1000 pg/ml), with the aim to to calculate the coefficients of variation (CVs). Results: The results demonstrated common changes in the CVs with changes in the number of tests for a given sample: the CVs decreased with increases in the number of tests from one to ten. All CV values were distributed within the range of 0.35 to 15.5%; as such, the CV values were all lower than the acceptable value of 20%. Conclusion: Based on this study, a single assay of Aβ1–40, Aβ1–42 and T-Tau, respectively, provides reliable results in terms of the measurement of that plasma biomarker.

Original languageEnglish
Pages (from-to)1015-1028
Number of pages14
JournalNeurology and Therapy
Volume10
Issue number2
DOIs
Publication statusPublished - 2021 Dec
Externally publishedYes

Keywords

  • Alzheimer’s disease
  • Immunomagnetic reduction
  • Plasma biomarkers

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction'. Together they form a unique fingerprint.

Cite this